WESTON, Fla., Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Cantex's azeliragon for the treatment of brain metastasis from breast cancer. This new azeliragon designation adds to azeliragon's two other Orphan Drug Designations for the treatment of pancreatic cancer and glioblastoma, received in mid-2024 and early 2023, respectively.

HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today announced that management will participate in a fireside chat and be available for one-on-one meetings at the 7th Annual Evercore HealthCONx Conference to be held in Coral Gables. Florida, December 3 – 5, 2024. 7th Annual Evercore HealthCONx Conference  Presentation Date:December 4, 2024  Time:7:55 – 8:15 AM ET  Webcast Link:click here   A live webcast of the presentation will be available via the Events section of the Company's investor relations website at https://ir.vtvtherapeut

HIGH POINT, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate developments. "Our cadisegliatin program continues to show promise as a new oral adjunct therapy being investigated for improvement in glycemic control and reduction of hypoglycemia in patients with type 1 diabetes. During the quarter, our team made progress addressing the basis for the clinical hold placed on our clinical program by the Food and Drug Adm

Cantor Fitzgerald initiated coverage of vTv Therapeutics with a rating of Overweight and set a new price target of $5.00

4 - vTv Therapeutics Inc. (0001641489) (Issuer)

4 - vTv Therapeutics Inc. (0001641489) (Issuer)

4 - vTv Therapeutics Inc. (0001641489) (Issuer)

4 - vTv Therapeutics Inc. (0001641489) (Issuer)

8-K - vTv Therapeutics Inc. (0001641489) (Filer)

8-K - vTv Therapeutics Inc. (0001641489) (Filer)

10-Q - vTv Therapeutics Inc. (0001641489) (Filer)

HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments. "Our newly appointed Chief Medical Officer, Dr. Thomas Strack, who has been working with us on a consulting basis for several months, is now leading our work on the cadisegliatin Phase 3 program with the goal of initiating studies as soon as possible," said Paul Sekhri, Chief Executive Offi

HIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced the appointment of Thomas Strack, M.D. as Chief Medical Officer, effective immediately. "I am pleased to welcome Dr. Strack to the vTv team," said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics. "He brings extensive drug development and clinical expertise, as well as a wealth of knowledge in endocrine, metabolic, and cardiovascular diseases. We believe his expertise will be invaluable as

HIGH POINT, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Elizabeth (Betzy) Keiley as Executive Vice President and General Counsel, effective immediately. "We welcome Betzy to vTv. Her years of legal expertise and deep experience in life sciences will be valuable to the vTv team," said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics. "Her decades of experience in both private practice and corporate settings make her an ideal fit for this position. I am confident that we wi

HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC ("CinPax"), a subsidiary of CinRx Pharma, LLC ("CinRx"). Under the terms of the agreements, CinPax acquired 4,154,549 shares of Class A Common Stock of vTv at an issue price of approximately $2.41 per share, with $6 million paid in cash at closing, and the remaining amount of $4 million payable on November 22, 2022. The agreements also provide for the issuance of 1.2 million warrants to CinRx to acquire additional shares of Class A Common Stock that become exercisable upon agreed vesting triggers (including FDA ap

SC 13G - vTv Therapeutics Inc. (0001641489) (Subject)

SC 13D/A - vTv Therapeutics Inc. (0001641489) (Subject)

SC 13D - vTv Therapeutics Inc. (0001641489) (Subject)